SHR‑7877
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 23, 2026
Jiangsu Hengrui Pharmaceuticals…announced that SHR‑7877 has received National Medical Products Administration (NMPA) approval to enter clinical trials in combination with HS‑20093 (with or without adebelisib) for the treatment of extensive‑stage small cell lung cancer (SCLC)
(flcube.com)
- "Next Steps: Phase I/II trial initiation expected Q2 2026; data may support breakthrough therapy designation and expedited NMPA review."
New P1/2 trial • Small Cell Lung Cancer
1 to 1
Of
1
Go to page
1